Brief: CF Pharmtech Says NMPA Accepts Clinical Trial Application For Olopatadine Hydrochloride And Mometasone Furoate Monohydrate Nasal Spray
17/12/2025 15:00
Dec 17 (Reuters) - CF PharmTech Inc 2652.HK: CLINICAL TRIAL APPLICATION FOR- OLOPATADINE HYDROCHLORIDE- AND MOMETASONE FUROATE MONOHYDRATE NASAL SPRAY- ACCEPTED BY NMPA Further company coverage: 2652.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CF PharmTech
See all newsBrief: CF Pharmtech Receives NMPA Implied Clinical Trial Approvals For ICF001 In IPF And PPF
Brief: CF Pharmtech To Place 21.7 MLN New H Shares At HK$13.82 Per Share
Brief: CF Pharmtech Says Nmpa Approves Ind Application For ICF004 As Class 1 New Drug
Brief: CF Pharmtech Inc To Nominate Zhang Jingjing As Candidate For Executive Director
CF PharmTech climbs most in 4 weeks on product marketing application in Asia